EUVIMEDEUVIMED entdecken
Crossref

Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy

Costanza Bertoni, Sara Diotallevi, Riccardo Lolatto, Girolamo Piromalli, Hamid Hasson, Alessia Siribelli, Sabrina Bagaglio, Caterina Uberti Foppa, Antonella Castagna, Giulia Morsica

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Costanza Bertoni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: HIV Infections, Hepatitis B, Chronic, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated factors associated with HBV‐rebound in people with HIV (PWH) with chronic HBV (CHBV) under HBV‐active antiretroviral therapy (ART): emtricitabine (FTC)+tenofovir alafenamide (TAF) or 3TC/FTC+ tenofovir disoproxil fumarate (TDF) regimen. The present study included PWH/CHBV followed as outpatients from October 2008 to August 2023 at San Raffaele Hospital, Milan, Italy. The baseline evaluation was the date of first negative HBV‐DNA (< 10 IU/mL) after the first positive result before HBV active ART. Last evaluation (LE) was the first HBV‐rebound (≥ 10 IU/mL) or last HBV undetectable in persistently HBV‐DNA negative PWH. Odds ratio (and corresponding 95% confidence interval) of HBV‐rebound, adjusted for nadir CD4 cells, ALT levels, and ART active on both viruses was estimated by multivariable logistic regression. Of 153 PWH/CHBV under ART active on both viruses, 25 (16.3%) had at least one HBV‐rebound. Multivariate analysis at LE, showed that PWH on 3TC/FTC had a higher probability of HBV‐rebound [adjusted odds ratio, aOR=4.88 (95%confidence interval, CI = 1.28, 20.10), p = 0.02], while PWH on FTC + TAF had lower probability of HBV‐rebound [aOR = 0.05 (95%CI = 0.002, 0.27), p = 0.005], both compared to those on 3TC/FCT + TDF. Hepatitis B‐rebound was associated with higher ALT levels [aOR=1.03 (95% CI = 1.01, 1.05) per 1‐U/L higher, p = 0.001]. FTC + TAF based ART seemed to be related to a better control of HBV‐DNA than 3TC/FTC + TDF and 3TC/FTC alone. Hepatitis B‐rebound may exert an effect on liver inflammation, as suggested by the increase of transaminases levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHepatitis B, ChronicAnti-HIV AgentsHumansMaleFemaleAdultMiddle AgedHepatitis B virusViral LoadTenofovirEmtricitabineItalyCoinfectionDNA, ViralAntiretroviral Therapy, Highly Active

Stichwörter der Autor:innen

ARTHBVHIVreboundstiffnesstenofovir

Substanzen

TenofovirEmtricitabineDNA, ViralAnti-HIV Agents

Autor:innen und Institutionen

  • Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Infectious Diseases, Vita-Salute University San Raffaele, Milan, Italy.

Förderung

  • This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Zitieren

APA

Bertoni, C., Diotallevi, S., Lolatto, R., Piromalli, G., Hasson, H., Siribelli, A., Bagaglio, S., Foppa, C. U., Castagna, A., & Morsica, G. (2025). Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy. Journal of Medical Virology. https://doi.org/10.1002/jmv.70573

Vancouver

Bertoni C, Diotallevi S, Lolatto R, Piromalli G, Hasson H, Siribelli A, et al. Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy. Journal of Medical Virology. 2025. doi:10.1002/jmv.70573

BibTeX
@article{Bertoni2025,
  author = {Bertoni, Costanza and Diotallevi, Sara and Lolatto, Riccardo and Piromalli, Girolamo and Hasson, Hamid and Siribelli, Alessia and Bagaglio, Sabrina and Foppa, Caterina Uberti and Castagna, Antonella and Morsica, Giulia},
  title = {Hepatitis B Viral Rebound in People With HIV Under HBV‐Active Antiretroviral Therapy},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70573}
}
Kostenlos starten →